BMRN Stock Recent News
BMRN LATEST HEADLINES
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end of 2024.
Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.D.
- Event to be webcast live and a replay will be available SAN RAFAEL, Calif. , Aug. 19, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an Investor Day with financial analysts and institutional investors on Wednesday, September 4, 2024, in New York City from 10:30 am to 1:00 pm Eastern Time.
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.
BioMarin Pharmaceutical Inc. BMRN announced an update on its Roctavian business to focus commercial operations on three markets: the U.S., Germany and Italy.
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.